POS1550 IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIAL

Abstract

BackgroundTYK2 mediates signaling of key cytokines (eg, IL-23) involved in plaque psoriasis (PsO) and psoriatic arthritis (PsA) pathogenesis. Deucravacitinib (DEUC) is a first-in-class, oral, selective, allosteric TYK2 inhibitor approved in...